A detailed history of Redmile Group, LLC transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, Redmile Group, LLC holds 3,072,478 shares of IGMS stock, worth $30 Million. This represents 3.32% of its overall portfolio holdings.

Number of Shares
3,072,478
Previous 3,072,478 -0.0%
Holding current value
$30 Million
Previous $21.1 Million 140.76%
% of portfolio
3.32%
Previous 1.38%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$8.68 - $17.36 $876,124 - $1.75 Million
100,936 Added 3.4%
3,072,478 $29.6 Million
Q2 2023

Aug 14, 2023

SELL
$8.86 - $14.0 $3.21 Million - $5.08 Million
-362,813 Reduced 10.88%
2,971,542 $27.4 Million
Q4 2021

Feb 14, 2022

SELL
$27.59 - $66.39 $2.51 Million - $6.05 Million
-91,100 Reduced 2.66%
3,334,355 $97.8 Million
Q3 2020

Nov 16, 2020

BUY
$43.0 - $84.01 $12.1 Million - $23.6 Million
281,455 Added 8.95%
3,425,455 $253 Million
Q3 2019

Nov 14, 2019

BUY
$17.75 - $24.3 $55.8 Million - $76.4 Million
3,144,000 New
3,144,000 $55.8 Million

Others Institutions Holding IGMS

About IGM Biosciences, Inc.


  • Ticker IGMS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,969,000
  • Market Cap $283M
  • Description
  • IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...
More about IGMS
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.